Plasmid-mediated fluoroquinolone resistance determinants are increasingly identified worldwide among various isolates of Enterobacteriaceae (9). Among them, QepA belongs to the major facilitator superfamily (MFS)-type group of efflux pumps. It was initially identified in Escherichia coli clinical isolates from Belgium and Japan (8, 13) . QepA (now QepA1) has subsequently been detected in E. coli isolates of human (1, 5, 10) and animal (6, 7) origins. QepA2, a two-amino-acid variant of QepA1, has been reported from an E. coli clinical isolate in France (2).
and multilocus sequence typing (MLST) (3, 12) . As a result, E. coli M3006 was classified into phylogenetic group D, with its allele combination corresponding to the sequence type (ST) 405. Phylogenetic group D-ST405 strains, along with phylogenetic group B2-ST131 strains, have been implicated as vehicles driving the international spread of bla CTX-M-15 (4) .
To the best of our knowledge, this is the first identification of a QepA-type efflux pump in the United States. The location of the multidrug-resistant, conjugative plasmid carrying qepA1, bla CTX-M-15 , and rmtB on a globally disseminated E. coli clone is a troubling phenomenon, as its presence simultaneously compromises the efficacy of fluoroquinolones, cephalosporins, and aminoglycosides that are commonly used in treatment of E. coli infections. 
